Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036086 | 0.73 | ACHE (0.48) | CES2CES1RAPGEF4 | |
| SCHEMBL449836 | 0.71 | — | — | |
| SCHEMBL5951582 | 0.69 | CA12 (0.33) | CA12CA1CA9 | |
| SCHEMBL979413 | 0.69 | ACHE (0.45) | CA1CA9CES2CES1PTGS2 | |
| SCHEMBL5701891 | 0.67 | RAPGEF4 (0.33) | CA12CA1CA9CES2CES1 | |
| SCHEMBL30577822 | 0.67 | CA12 (0.57) | CA12CA1CA9CES2CES1 | |
| SCHEMBL29032005 | 0.67 | CA12 (0.57) | CA12CA1CA9CES2CES1 | |
| SCHEMBL29031998 | 0.67 | CA12 (0.57) | CA12CA1CA9CES2CES1 | |
| SCHEMBL28455177 | 0.67 | CA12 (0.57) | CA12CA1CA9CES2CES1 | |
| SCHEMBL5952984 | 0.65 | ALDH1A1 (0.42) | RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329668-B2 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-12 | — | — | US | disclosed |
| US-20040204432-A1 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004075846-A2 | PYRAZOLOPURINE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-10 | — | — | WO | disclosed |
| US-6352798-B1 | Phenyl boron-based compounds as anion receptors for non-aqueous battery electrolytes | BROOKHAVEN SCIENCE ASSOCIATES, LLC | 2002-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204432-A1 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, HPRT1, TYMP | CA12 4199/4885CA1 4006/4885CA9 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.